This article was originally published here
Pharmacogenomics. 2021 Sep 14. doi: 10.2217/pgs-2021-0061. Online ahead of print.
Aim: To compare the cost-effectiveness of olaparib versus control treatment in metastatic castration-resistant prostate cancer patients with at least one gene mutation in BRCA1, BRCA2 or ATM from the US payer perspective. Methods: A Markov model was constructed to assess the quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios. Sensitivity analyses and scenario analyses were conducted to explore the impact of uncertainties. Results: The base-case result indicated that, for patients with specific gene mutations, olaparib gained 1.26 QALYs and USD$ 157,732 total cost. Compared with control treatment, the incremental cost-effectiveness ratio of olaparib was USD$ 248,248/QALY. The price of olaparib was the most influential parameter. Conclusion: Olaparib is not cost-effective in comparison with control treatment in metastatic castration-resistant prostate cancer patients with specific gene mutations.